Cyrus K. Mirsaidi is the current chairman and managing partner of BioSelective Capital Investments, a Utah-based risk-capital biotech investment company with focus on early stage therapeutics and select translational opportunities. He is co-founder of BioArdis and a member of its Board of Directors.
In addition, Mr. Mirsaidi is an executive committee member and operating partner at Bridgewest Ventures, New Zealand, serves in Advisory roles with Advent International, and is on the Board of BioDuro-Sundia, a contract research, development and manufacturing company, where he served as President and CEO from 2015 to 2021. Prior to BioDuro-Sundia, Mr. Mirsaidi served as CEO of Formex, was the founder and CEO of Molecular Response, and served in key executive roles at AltheaDx, Ontogen, Inc. and Quest Diagnostics.
Mr. Mirsaidi received a BS in Biology from University of California, Irvine. Mr. Mirsaidi resides in Deer Valley, Utah, and relishes in sharing the wines he makes in his spare time with family and friends.